Dongdong Zhou

570 total citations
29 papers, 389 citations indexed

About

Dongdong Zhou is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Dongdong Zhou has authored 29 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Cancer Research and 8 papers in Molecular Biology. Recurrent topics in Dongdong Zhou's work include Lung Cancer Treatments and Mutations (3 papers), Liver Disease Diagnosis and Treatment (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Dongdong Zhou is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Liver Disease Diagnosis and Treatment (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Dongdong Zhou collaborates with scholars based in China and United Kingdom. Dongdong Zhou's co-authors include Teng Pan, Lixia Cao, Zhendong Shi, Jingjing Liu, Shaorong Zhao, Jin Zhang, Yanyan Xuan, Shuyong Zhang, Chao Zheng and Dexian Zheng and has published in prestigious journals such as Oncogene, Scientific Reports and Cancer Letters.

In The Last Decade

Dongdong Zhou

28 papers receiving 384 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dongdong Zhou China 12 210 146 99 50 46 29 389
Surong Zhao China 11 247 1.2× 198 1.4× 80 0.8× 30 0.6× 30 0.7× 25 364
Linfei Hu China 13 268 1.3× 119 0.8× 104 1.1× 39 0.8× 68 1.5× 34 451
Yingfeng Zhu China 10 338 1.6× 200 1.4× 74 0.7× 47 0.9× 36 0.8× 17 459
Mehrdokht Sadrkhanloo Iran 8 245 1.2× 180 1.2× 88 0.9× 24 0.5× 57 1.2× 10 381
Zhenkun Xia China 12 238 1.1× 114 0.8× 85 0.9× 44 0.9× 54 1.2× 34 407
Heqing Yi China 12 215 1.0× 154 1.1× 68 0.7× 109 2.2× 37 0.8× 25 418
Baomin Shi China 9 218 1.0× 149 1.0× 87 0.9× 35 0.7× 90 2.0× 14 379
Guoqiang Yan China 13 235 1.1× 132 0.9× 75 0.8× 51 1.0× 26 0.6× 25 382
Li Xiao China 11 199 0.9× 127 0.9× 41 0.4× 32 0.6× 29 0.6× 26 368
Chien-Yu Chen United States 5 314 1.5× 157 1.1× 86 0.9× 60 1.2× 40 0.9× 7 475

Countries citing papers authored by Dongdong Zhou

Since Specialization
Citations

This map shows the geographic impact of Dongdong Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dongdong Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dongdong Zhou more than expected).

Fields of papers citing papers by Dongdong Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dongdong Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dongdong Zhou. The network helps show where Dongdong Zhou may publish in the future.

Co-authorship network of co-authors of Dongdong Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Dongdong Zhou. A scholar is included among the top collaborators of Dongdong Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dongdong Zhou. Dongdong Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ren, Yuqing, Anning Zuo, Shutong Liu, et al.. (2025). Cancer-associated fibroblasts drive lung adenocarcinoma progression via THBS2-mediated epithelial-mesenchymal transition. Oncogene. 44(44). 4284–4297.
2.
Zhou, Dongdong, Erjiang Tang, Wenjun Wang, et al.. (2025). Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer. Cell Reports Medicine. 6(6). 102158–102158. 3 indexed citations
3.
Zhou, Dongdong, et al.. (2025). Survival analysis of patients with hepatocellular carcinoma based on the ratio of platelet count to spleen diameter. Frontiers in Pharmacology. 15. 1449603–1449603. 1 indexed citations
4.
Liu, Hongfu, Dongdong Zhou, Kai Zhang, et al.. (2024). Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer. Cell Death and Disease. 15(3). 187–187. 12 indexed citations
5.
Xuan, Yanyan, et al.. (2024). Association between RC/HDL-C ratio and risk of non-alcoholic fatty liver disease in the United States. Frontiers in Medicine. 11. 1427138–1427138. 6 indexed citations
6.
Xuan, Yanyan, et al.. (2024). Elevated ALT/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States. Frontiers in Endocrinology. 15. 1457598–1457598. 28 indexed citations
7.
Xuan, Yanyan, Minghui Zhu, Linzhi Xu, et al.. (2024). Elevated non-HDL-C to HDL-C ratio as a marker for NAFLD and liver fibrosis risk: a cross-sectional analysis. Frontiers in Endocrinology. 15. 1457589–1457589. 8 indexed citations
8.
9.
10.
Su, Mu, Jinxing Zhou, Dongdong Zhou, et al.. (2023). Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer. Frontiers in Genetics. 14. 1125970–1125970. 5 indexed citations
11.
Song, Zheng, et al.. (2022). Changes in Ki-67 in Residual Tumor and Outcome of Primary Inflammatory Breast Cancer Treated With Trimodality Therapy. Clinical Breast Cancer. 22(5). e655–e663. 3 indexed citations
12.
Zhao, Mindi, Zhengguang Guo, Tao Yuan, et al.. (2022). Urinary proteomic analysis during pregnancy and its potential application in early prediction of gestational diabetes mellitus and spontaneous abortion. Annals of Translational Medicine. 10(13). 736–736. 3 indexed citations
13.
Hao, Xiaomeng, Yufan Qiu, Lixia Cao, et al.. (2021). Over-Expression of Centromere Protein U Participates in the Malignant Neoplastic Progression of Breast Cancer. Frontiers in Oncology. 11. 615427–615427. 5 indexed citations
14.
Cao, Lixia, Shaorong Zhao, Zhendong Shi, et al.. (2021). Chidamide Combined With Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer. Frontiers in Oncology. 11. 614458–614458. 12 indexed citations
15.
Liu, Xiaoyan, et al.. (2020). Urinary metabolomic investigations in vitiligo patients. Scientific Reports. 10(1). 17989–17989. 14 indexed citations
16.
Yang, Tao, et al.. (2019). Protective effects of catalpol and rhein in murine experimental autoimmune encephalomyelitis via regulation of T helper (Th) 1, Th2, Th17, and regulatory T cell responses.. PubMed. 39(6). 809–817. 6 indexed citations
17.
Pan, Teng, et al.. (2019). FBXL19-AS1 promotes cell proliferation and inhibits cell apoptosis via miR-876-5p/FOXM1 axis in breast cancer. Acta Biochimica et Biophysica Sinica. 51(11). 1106–1113. 22 indexed citations
18.
Zhang, Shuyong, Chao Zheng, Wan Zhu, et al.. (2019). A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors. Theranostics. 9(18). 5412–5423. 18 indexed citations
19.
Pan, Teng, Dongdong Zhou, Zhendong Shi, et al.. (2019). Centromere protein U (CENPU) enhances angiogenesis in triple-negative breast cancer by inhibiting ubiquitin–proteasomal degradation of COX-2. Cancer Letters. 482. 102–111. 27 indexed citations
20.
Duan, Zhijun, Hang Yang, Lixia Wang, et al.. (2018). Home‐Based Transcutaneous Neuromodulation Improved Constipation via Modulating Gastrointestinal Hormones and Bile Acids. Evidence-based Complementary and Alternative Medicine. 2018(1). 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Surong Zhao Breakdown of academic impact, for papers by Linfei Hu Breakdown of academic impact, for papers by Yingfeng Zhu Breakdown of academic impact, for papers by Mehrdokht Sadrkhanloo Breakdown of academic impact, for papers by Zhenkun Xia Breakdown of academic impact, for papers by Heqing Yi Breakdown of academic impact, for papers by Baomin Shi Breakdown of academic impact, for papers by Guoqiang Yan Breakdown of academic impact, for papers by Li Xiao Breakdown of academic impact, for papers by Chien-Yu Chen
Rankless by CCL
2026